NCT01841723 2026-03-18
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT04840602 2026-03-18
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03204188 2026-01-30
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01849263 2025-09-10
Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02581930 2025-09-08
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01500733 2024-09-19
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT02514083 2024-09-19
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04209621 2022-03-09
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02129062 2017-01-16
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated